Ginkgo bioworks reports fourth quarter and full year 2024 financial results

Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target cell engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 boston , feb. 25, 2025 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended december 31, 2024. the update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking